The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Oxcarbazepine for Mood Disorders

To the editor: The Food and Drug Administration approved oxcarbazepine on Jan. 14, 2000, for the treatment of epilepsy. It has been reported to be effective in the treatment of mood disorders (1, 2). This report is about four Caucasian patients with bipolar II disorder with comorbid substance abuse who experienced significant improvement with oxcarbazepine.

Mr. A was a 52-year-old married man who was referred by a therapist in his employment assistance program for hostile behavior, which affected his relationships with family members and co-workers. He had been treated unsuccessfully with divalproate and psychotherapy. He began oxcarbazepine monotherapy, up to 1200 mg/day. He experienced better work productivity, an absence of physical violence toward his wife and co-workers, and fewer depressive days. He reported no side effects.

Ms. B was a 27-year-old single woman who was in treatment for childhood sexual abuse, self-mutilation, several suicide attempts, and episodic violent behavior. Since her adolescence, she had been in numerous inpatient and outpatient treatments, which had not produced significant improvement in her symptoms or function. Oxcarbazepine was initially added to her regimen of lorazepam, buproprion, fluvoxamine, trazodone, quetiapine, levothyroxine, and modafinil. Over the next year, she reduced her medications to oxcarbazepine, 600 mg b.i.d., levothyroxine, and trazodone. She had no hospitalizations and no temper outbursts or depressive episodes, was working full-time, and was not receiving Medicaid.

Mr. C was a 40-year-old married man who was referred to the clinic for treatment of agitation and conflict with his wife. He was taking buspirone, buproprion, and lithium. Oxcarbazepine, up to 1200 mg/day, was added to his dose of lithium, 900 mg/day. His irritability decreased, his depression lifted, his relationship with his wife improved, and he obtained full-time employment. In the past year, he has been well maintained with oxcarbazepine, 1200 mg b.i.d., and modafinil, 400 mg/day, before his shift work.

Mr. D was a 33-year-old man who was referred for treatment of domestic violence. He began oxcarbazepine monotherapy, up to 1200 mg/day. Since then, he has controlled his angry outbursts, felt happier, improved his home life, reduced his alcohol and cannabis consumption to occasional use, and given up his part-time job as a bar bouncer. His friends have also noted the improvement.

These patients were initially given 150 mg/day of oxcarbazepine; the dose was increased every 3–4 days by 150 mg until it reached 600 mg at bedtime. Morning dosing was then added, as needed, up to the maximum dose reported per patient. None of these patients had developed hyponatremia when tested within 1 month of initiation of treatment.

These patients showed improvement in mood stabilization. Oxcarbazepine was well tolerated and was the initiating factor in decreasing their symptoms of anger and irritability, as well as their depressive symptoms. We have also reported separately on the benefits of oxcarbazepine in a series of 87 patients with various subtypes of mood disorders (3). Prospective, double-blind, placebo-controlled trials of oxcarbazepine are indicated.

References

1. Emrich HM, Altmann H, Dose M, von Zerssen D: Therapeutic effects of GABA-ergic drugs in affective disorders: a preliminary report. Pharmacol Biochem Behav 1983; 19:369-372Crossref, MedlineGoogle Scholar

2. Emrich HM, Dose M, von Zerssen D: The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8:243-250Crossref, MedlineGoogle Scholar

3. Nasr SJ, Casper ML: Oxcarbazepine use in the treatment of mood disorders, in 2002 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, p 117Google Scholar